World Hepatitis Day 2020 image

Statement from the National Association of County and City Health Officials on World Hepatitis Day

Jul 27, 2020 | Andrea Grenadier

Statement from the National Association of County and City Health Officials on World Hepatitis Day

July 28, 2020

The National Association of County and City Health Officials (NACCHO), on behalf of the nearly 3,000 local health departments across the country, recognizes World Hepatitis Day, acknowledging the magnitude and impact of viral hepatitis, which causes significant illness and kills more Americans than any other infectious disease. Local health departments are leaders in the fight against viral hepatitis, engaged in surveillance, prevention, diagnosis, and treatment of viral hepatitis.

Tools to eliminate viral hepatitis in the United States include highly-effective vaccines against hepatitis A (HAV) and B (HBV); harm reduction strategies that could prevent half of hepatitis C cases (HCV); and curative treatments for HCV that can prevent deaths and further transmission. However, social and structural barriers to viral hepatitis services are driving a dramatic rise in HCV and widespread outbreaks of HAV. Moreover, additional investments are needed to scale up services and address the root causes of hepatitis and the inequities that define its distribution and impact in the U.S.

“While the nation is focused on addressing the COVID-19 pandemic, the spread of viral hepatitis continues,” said Lori Tremmel Freeman, NACCHO’s Chief Executive Officer. “We have the tools to eliminate viral hepatitis in the U.S., but social and structural barriers, stigma and discrimination, and insufficient funding limit access to prevention, diagnosis, and care. We need to redouble our efforts to support the work of local health departments to continue their work to prevent the spread and cure those infected.”

In 2017, the National Academies of Science, Engineering, and Medicine released a groundbreaking report declaring the feasibility of hepatitis elimination in the U.S., laying out a plan for the elimination of HBV and HCV. However, since then, cases have continued to rise. More than 30 states have reported outbreaks of HAV since 2016, and injection drug use has advanced the spread of HBV and HCV, resulting in a four-fold increase in HCV cases and state-level increases in HBV in the states hit hardest by the opioid epidemic.

Despite the availability of highly effective vaccines against HAV and HBV, vaccine coverage remains low: less than 10% of adults are vaccinated against HAV and only 25% of adult are vaccinated against HBV in the U.S. Half of people living with HCV and two-thirds of those

living with HBV don’t know their status, demonstrating the need for routine testing. While HCV can now be cured with limited side effects in less than three months, many people are unable to access this costly treatment. Putting the U.S. on a path toward hepatitis elimination would cost $3.9 billion over 10 years—an investment which would save the U.S. $6.5 billion annually. And yet, the Centers for Disease Control and Prevention receives less than 10% of what it needs to fund its work against viral hepatitis, a trend that is mirrored at the local level

These gaps in prevention, testing, and care are driven by social and structural barriers that limit access to viral hepatitis services: people who use drugs, people experiencing unstable housing or homelessness, people who are currently or were recently incarcerated, and men who have sex with men are all disproportionately affected by viral hepatitis in the U.S. These populations also face heightened stigma, discrimination, and other barriers when seeking healthcare.

While syringe services programs can prevent half of new HCV cases, many jurisdictions ban such programs, based on incorrect assumptions about their safety and efficacy. Even in those places with established programs, pandemic-related social distancing procedures and resources constraints also pose unique challenges to these important programs. People experiencing unstable housing or homelessness report substantial unmet health needs and may not be able to consistently utilize sanitation and hygiene practices that could protect them from HAV. The prevalence of HCV in U.S. prisons ranges from 10 to 40%, compared to a national prevalence of 1%. This drives community spread, with HCV prevalence 10-20 times higher in communities near correctional facilities. Yet the criminal justice system fails to provide viral hepatitis services—with less than 1% of HCV-positive inmates accessing treatment in state prisons —and the stigma associated with a criminal record impedes access to employment, and in turn health insurance.

For more information about NACCHO’s infectious disease program initiatives, visit its HIV, STI, and Viral Hepatitis webpage.




About Andrea Grenadier

More posts by Andrea Grenadier

Related Posts

  • HIV, STI, & Viral Hepatitis

NACCHO partners with Altarum on “Congenital Syphilis...

A study was conducted among women who received prenatal care in a current or...

Jul 10, 2025 | Rebekah Horowitz

NACCHO partners with Altarum on “Congenital Syphilis...

  • HIV, STI, & Viral Hepatitis

New Report on Routine Opt-Out Syphilis Testing in...

NACCHO funded 3 LHD’s to partner with their local women’s jail to evaluate the...

Jun 03, 2025 | Rebekah Horowitz

New Report on Routine Opt-Out Syphilis Testing in...

FLEXED LC Applications Open
  • ID Featured, Infectious Disease

Join NACCHO’s Flexible Local Epidemiology for X-factor...

Learn more about NACCHO’s Flexible Local Epidemiology for X-factor Emerging...

May 30, 2025 | Jaclyn Abramson

Join NACCHO’s Flexible Local Epidemiology for X-factor...

Webinar
  • Webinar, Infection, Prevention, and Control

Strengthening Public Health / Healthcare Relationships...

On June 24, 2025, NACCHO hosted a 4-hour workshop on strengthening public...

May 23, 2025 | Candice Young

Strengthening Public Health / Healthcare Relationships...

  • HIV, STI, & Viral Hepatitis

New Report Highlights Opportunities and Lessons Learned...

This report offers concrete insights and recommendations for local health...

May 19, 2025 | Kat Kelley

New Report Highlights Opportunities and Lessons Learned...

Webinar
  • Webinar, Infection, Prevention, and Control

Data Use and Visualization for IPC: A Three-Part...

NACCHO hosted a comprehensive training series for LHD staff engaged in...

May 19, 2025 | Candice Young

Data Use and Visualization for IPC: A Three-Part...

Hepatitis Awareness Month 2025 Blog Post Image
  • HIV, STI, & Viral Hepatitis

Hepatitis Awareness Month 2025

Hepatitis Awareness Month is time to raise awareness about viral hepatitis and...

May 06, 2025 | Kat Kelley

Hepatitis Awareness Month 2025

AI Webinar Series
  • Webinar

Two-Part Webinar Series: Building AI Readiness in Public...

NACCHO hosted a two-part webinar series on how public health professionals can...

May 05, 2025 | Gelilawit Tamrat, Kristen Ross

Two-Part Webinar Series: Building AI Readiness in Public...

  • HIV, STI, & Viral Hepatitis

CDC Releases 2023 Viral Hepatitis Surveillance and 2025...

CDC reported on trends in hepatitis A, B, and C as well as national progress...

Apr 30, 2025 | Kat Kelley

CDC Releases 2023 Viral Hepatitis Surveillance and 2025...

Back to Top